News

B. Riley Securities initiated coverage on ArriVent Biopharma, a clinical-stage biopharmaceutical company focused on developing cancer treatments. The firm believes ArriVent's lead drug candidate, firmonertinib, has the potential to be a superior treatment option for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations and PACC mutations, representing a significant market opportunity.

Monte Rosa Therapeutics' Phase 1 study of MRT-6160 demonstrated promising results, with sustained VAV1 degradation and suppression of T and B cell activation, paving the way for Phase 2 studies and potential applications in immune-mediated diseases. The company's collaboration with Novartis and strong financial position further bolster its prospects.

Nike Inc. (NKE) surpassed analyst expectations in the third quarter of fiscal 2025, reporting revenue of $11.27 billion and earnings per share of 54 cents, driven by strong performance in the Nike Direct and Nike Brand segments. Despite a 9% year-over-year decline in total revenue, the company remains optimistic about its future prospects.

Cryptocurrency prices saw a slight retracement on Thursday following President Trump's address to investors, with analysts remaining cautiously optimistic about the market's future. Key data points include increased daily active addresses and large transactions, while traders anticipate potential new highs before year-end.

Sunnova Energy International Inc. (NOVA) shares surged 40.4% on Thursday after reports that Oaktree Capital Management has been acquiring the company's debt as it prepares for debt restructuring negotiations with creditors. Oaktree has accumulated approximately $400 million of Sunnova's debt, positioning itself as a key player in the upcoming discussions.